Curis (CRIS) Set to Announce Earnings on Thursday

Curis (NASDAQ:CRIS) is set to release its earnings data before the market opens on Thursday, August 1st. Analysts expect Curis to post earnings of ($1.70) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Curis (NASDAQ:CRIS) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.94) by ($0.11). Curis had a negative return on equity of 224.75% and a negative net margin of 486.45%. The company had revenue of $2.09 million for the quarter, compared to the consensus estimate of $2.31 million. During the same quarter in the previous year, the company posted ($2.40) EPS. On average, analysts expect Curis to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Curis Stock Performance

CRIS traded down $0.30 on Tuesday, hitting $5.75. 18,054 shares of the company were exchanged, compared to its average volume of 32,242. Curis has a 12 month low of $3.80 and a 12 month high of $17.49. The company has a market cap of $33.87 million, a PE ratio of -0.66 and a beta of 3.36. The stock’s fifty day moving average is $8.03 and its 200-day moving average is $10.72.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CRIS. HC Wainwright reiterated a “buy” rating and set a $26.00 target price on shares of Curis in a report on Wednesday, May 15th. Truist Financial restated a “buy” rating and issued a $26.00 price objective on shares of Curis in a research note on Wednesday, May 15th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Curis in a research note on Wednesday, May 15th.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.